Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

David Younger says his company's model training showed that solving truly hard protein design problems will require much more data than the field expects. He also warns public binding and affinity data are often not interoperable, lack proper controls, and lack annotations, making them hard to reuse.

Related Insights

To evolve AI from pattern matching to understanding physics for protein engineering, structural data is insufficient. Models need physical parameters like Gibbs free energy (delta-G), obtainable from affinity measurements, to become truly predictive and transformative for therapeutic development.

Public datasets primarily show successful protein interactions, starving AI models of crucial "negative data"—plausible but incorrect interactions. A-Alpha Bio finds that providing this data on what fails is just as important for training predictive and generalizable models.

Machine learning's application in multi-specific antibody design is hampered by a lack of public data. Companies must invest heavily in generating their own large-scale, proprietary datasets to train effective models, creating a significant barrier to entry and a competitive advantage.

To break the data bottleneck in AI protein engineering, companies now generate massive synthetic datasets. By creating novel "synthetic epitopes" and measuring their binding, they can produce thousands of validated positive and negative training examples in a single experiment, massively accelerating model development.

Younger says model makers evaluate on unique bespoke targets, so pharma buyers cannot tell which model is best. He is working with companies on a benchmark that standardizes target difficulty and characterizes tens of thousands of designs, hoping to get true apples-to-apples comparisons with tighter error bars.

The issue with public protein affinity databases isn't just a lack of data, but a lack of interoperability. Data aggregated from different labs using varied methods, buffers, and conditions creates a "messy" dataset that hinders an AI's ability to learn generalizable rules, a problem solved by standardized assays.

The low-hanging fruit of applying AI to existing datasets is being picked. The next major leap forward will come not from slightly better models, but from creative strategies to generate entirely new datasets for unsolved problems like protein stability or in vivo effects.

Current AI for protein engineering relies on small public datasets like the PDB (~10,000 structures), causing models to "hallucinate" or default to known examples. This data bottleneck, orders of magnitude smaller than data used for LLMs, hinders the development of novel therapeutics.

Standard co-folding models struggle with induced proximity because public databases like the PDB lack sufficient training data for multi-protein complexes. Because dynamic multi-protein complexes take on endless conformations, standard AI models become overconfident and inaccurate. To solve this, Protai generates proprietary structural proteomics data that maps physical distances and conformations, enabling accurate modeling of complexes that can be targeted by molecular glues and PROTACs.

Younger says the Protein Data Bank today holds about 10,000 antibody-antigen structures and adds roughly 1,000 yearly. Their internal scaling work suggests good generalizable de novo design models may need hundreds of thousands to millions of structures, so waiting on PDB growth is far too slow.